Watch AMRX. Know when insiders buy.
One email the day a filing lands. Free.
AMRX
Amneal Pharmaceuticals, Inc.
17.44
−0.43 −2.41%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
19
FLAG · shorts 19
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $5.6BP/E 35.6DIV YIELD —FCF YIELD 2.30%REV TTM $3.1B +9.3%NET INCOME $157.4M +4562.6%NET DEBT $2.4B52W 9.60 – 19.10SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $796.2M | +9.9% | 42.0% | $129.8M | $57.7M | +157.2% | 0.18 | −$21.2M | $30.7M | −$51.9M | Aug 6 |
| Q1 2026 · Mar 31 | $722.5M | +3.9% | 44.3% | $141.8M | $62.3M | +410.5% | 0.19 | −$26.7M | $8.2M | −$34.9M | May 7 |
| Q4 2025 · Dec 31derived | $814.3M | +11.5% | 36.5% | $112M | $35.1M | — | 0.11 | $130.3M | $21.8M | $108.5M | Feb 27 |
| Q3 2025 · Sep 30 | $784.5M | +11.7% | 34.9% | $70.3M | $2.4M | — | 0.01 | $118.5M | $12.3M | $106.2M | Nov 6 |
| Q2 2025 · Jun 30 | $724.5M | +3.2% | 39.5% | $111.4M | $22.4M | +274.0% | 0.07 | $83.8M | $22.8M | $61M | Aug 6 |
| Q1 2025 · Mar 31 | $695.4M | +5.5% | 36.8% | $100.3M | $12.2M | — | 0.04 | $7.4M | $13.2M | −$5.8M | May 7 |
| Q4 2024 · Dec 31derived | $730.5M | +18.4% | 36.0% | $75.8M | −$31.1M | — | -0.10 | $118.1M | $15.2M | $102.9M | Feb 27 |
| Q3 2024 · Sep 30 | $702.5M | +13.3% | 38.4% | $88.8M | −$156K | −101.6% | 0.00 | $141.8M | $16.9M | $124.8M | Nov 6 |
| Q2 2024 · Jun 30 | $701.8M | — | 35.6% | $95.5M | $6M | — | 0.02 | $39.7M | $10.6M | $29M | Aug 7 |
| Q1 2024 · Mar 31 | $659.2M | — | 36.1% | −$10.7M | −$91.6M | — | -0.30 | −$4.4M | $9.2M | −$13.6M | May 7 |
| Q4 2023 · Dec 31derived | $617M | — | 30.8% | $14.2M | −$98.6M | — | -0.57 | $135.8M | $9.9M | $126M | Feb 27 |
| Q3 2023 · Sep 30 | $620M | — | 37.5% | $75.6M | $9.7M | — | 0.06 | $81.4M | $11.7M | $69.7M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $3B | 36.9% | $394.1M | $72.1M | 2.4% | 0.22 | $340M | $70.1M | $269.9M | — | — |
| FY2024 · to Dec 31 | $2.8B | 36.5% | $249.3M | −$116.9M | -4.2% | -0.38 | $295.1M | $51.9M | $243.2M | — | — |
| FY2023 · to Dec 31 | $2.4B | 34.3% | $204.4M | −$84M | -3.5% | -0.48 | $345.6M | $43.2M | $302.4M | — | — |
| FY2022 · to Dec 31 | $2.2B | 35.5% | −$94.9M | −$270.6M | -12.2% | -0.86 | $65.1M | $46.4M | $18.7M | — | — |
| FY2021 · to Dec 31 | $2.1B | 36.7% | $152.7M | $13.2M | 0.6% | 0.07 | $241.8M | $47.7M | $194.1M | — | — |
| FY2020 · to Dec 31 | $2B | 31.5% | $91.2M | $67.8M | 3.4% | 0.61 | $379M | $56.4M | $322.6M | — | $0 |
Every number comes from Amneal Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.